LLY ▼ -0.4% - Eli Lilly and Company $LLY - Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL 02-OCT-2026 03:06 PM ET